International Clinical Psychopharmacology最新文献_第10页

When antidepressants meet the gut microbiota: implications and challenges. 当抗抑郁药遇到肠道菌群：影响和挑战。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000558

Sofia Cussotto, Romain Colle, Denis J David, Emmanuelle Corruble

引用次数: 0

Dropped-Head syndrome: a possible new variant of clozapine-induced inflammation during titration. 低垂头综合征：氯氮平在滴定过程中引起炎症的一种可能的新变体。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000507

Paula Jhoana Escobedo-Aedo, Irene Pans, Enrique Baca-García, Jose de Leon, María-Luisa Barrigón, Santiago Ovejero

引用次数: 0

Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report. 病例报告：一名耐药抑郁症患者使用埃司氯胺酮鼻内喷雾剂后出现的自发分离症状。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-01-22 DOI: 10.1097/YIC.0000000000000527

Louis Chevalier, Samuel Bulteau, Louis Cheval, Jalal Charron, Anne Sauvaget, Andrew Laurin

{"title":"Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report.","authors":"Louis Chevalier, Samuel Bulteau, Louis Cheval, Jalal Charron, Anne Sauvaget, Andrew Laurin","doi":"10.1097/YIC.0000000000000527","DOIUrl":"10.1097/YIC.0000000000000527","url":null,"abstract":"Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted at a distance, often accompanied by anxiety. Delayed dissociative phenomena disappeared within the fourth week of treatment by esketamine. The literature mainly discusses dissociation during esketamine treatment sessions, with limited data on differed spontaneous episodes. Three hypotheses are discussed concerning the mechanism of occurrence of these dissociative phenomena, including esketamine's direct effect, central nervous system sensitization, and anxiety-induced dissociation. We present the first case of differed spontaneous dissociative effects after intranasal esketamine administration for treatment-resistant depression. Our main hypothesis suggests that esketamine may act as a 'pattern' for dissociative experiences, heightening the patient's ability to discern these phenomena during other instances of dissociation, such as acute anxiety attacks. Further research is needed to validate this hypothesis.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"37-40"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials. 卡利普嗪辅助治疗重度抑郁障碍的安全性和耐受性：2b期/3期临床试验的汇总分析。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000528

Michael E Thase, Paul P Yeung, Ludmyla Rekeda, Meng Liu, Shane Varughese

{"title":"Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials.","authors":"Michael E Thase, Paul P Yeung, Ludmyla Rekeda, Meng Liu, Shane Varughese","doi":"10.1097/YIC.0000000000000528","DOIUrl":"10.1097/YIC.0000000000000528","url":null,"abstract":"To characterize the safety and tolerability of adjunctive cariprazine in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT). Post hoc analyses evaluated pooled data from 2 fixed-dose phase 3 cariprazine studies (1.5 and 3 mg/d [approved doses for MDD]). In a separate safety analysis, cariprazine 0.1-4.5 mg/d was evaluated using data from the 2 fixed-dose trials plus 3 flexible-dose studies grouped by modal-daily dose. In the pooled phase 3 studies (placebo = 503, 1.5 mg/d = 502, 3 mg/d = 503), overall cariprazine-treated patients had high rates of study completion (90%). Patients had mostly mild/moderate treatment-emergent adverse events that caused premature discontinuation of 4.3%. Only akathisia, nausea, and insomnia occurred in ≥5% of cariprazine patients (any group) and at twice the rate of placebo; potential dose-dependent responses were observed for akathisia and insomnia. Cariprazine had a neutral metabolic profile, with mean weight increase of <1 kg. Modal-dose results were similar, and both analyses were consistent with the known safety profile of cariprazine across its approved indications. Adjunctive cariprazine therapy was safe and generally well tolerated in patients with MDD who had not obtained an adequate response to ADT monotherapy; no new safety signals were identified.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"27-36"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding mood disorder treatments. 了解情绪障碍的治疗方法。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000573

Alessandro Serretti

引用次数: 0

A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. 文拉法辛和纳曲酮预防曲马多所致阿片类药物使用障碍患者复发的疗效比较研究。

IF 3 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000487

Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly

{"title":"A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol.","authors":"Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly","doi":"10.1097/YIC.0000000000000487","DOIUrl":"10.1097/YIC.0000000000000487","url":null,"abstract":"Tramadol and venlafaxine share similar pharmacological characteristics that may allow for overlapping therapeutic indications for them. The objective of this study was to compare the efficacy of venlafaxine and naltrexone in the treatment of tramadol abuse. This comparative trial included 95 patients with tramadol abuse who were detoxified for 2 weeks. Twenty-eight participants underwent the maintenance phase, while the remaining participants (n = 67) dropped out. The patients were randomized to use 50 mg/day of naltrexone or 225 mg/day of venlafaxine for 8 weeks. All participants were interviewed using SCID-I (DSM-IV-TR) criteria for diagnosing substance use and other psychiatric disorders. The proportion of relapsed patients was comparable between the naltrexone and venlafaxine groups (29.4% vs. 30.4%, P = 0.9). However, participants in the venlafaxine group stayed in treatment longer than participants in the naltrexone group, and the difference was significant (22.9 ± 7.89 days vs. 16.9 ± 3.4 days, P = 0.01). Only psychiatric comorbidity was found to be significantly associated with retention in treatment (80% vs. 22%, P = 0.005). Venlafaxine is as effective as naltrexone in preventing relapse in patients with tramadol abuse. Venlafaxine was more effective than naltrexone in treatment retention.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"341-349"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients. 英国医用大麻登记处：分析医用大麻治疗广泛性焦虑症患者临床疗效的病例系列。

IF 3 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-02-02 DOI: 10.1097/YIC.0000000000000536

Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren

{"title":"UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients.","authors":"Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren","doi":"10.1097/YIC.0000000000000536","DOIUrl":"10.1097/YIC.0000000000000536","url":null,"abstract":"This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome measures (PROMs) from baseline up to 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L. Adverse events were recorded using CTCAE version 4.0. A total of 120 patients were identified for inclusion, of which 38 (31.67%), 52 (43.33%), and 30 (25.00%) were prescribed oils, dried flower, and both formulations of CBMP. Associated improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, 6, and 12 months were observed compared to baseline ( P < 0.010). There were 24 (20.00%) patients who reported 442 (368.33%) adverse events, most of which were mild (n = 184, 41.63%) and moderate (n = 197, 44.57%). This study reports an association between initiation of a homogeneous CBMP therapy and improvements in anxiety severity and HRQoL in individuals with GAD. Moreover, therapy was well-tolerated at 12 months follow-up. Further investigation through randomized controlled trials will ultimately be required to determine causation.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"350-360"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venlafaxine for tramadol dependence and medical cannabis therapy for generalized anxiety disorder. 文拉法辛治疗曲马多依赖症和医用大麻治疗广泛性焦虑症。

IF 3 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-09-25 DOI: 10.1097/YIC.0000000000000567

Alessandro Serretti

引用次数: 0

The impact of efficacy of long-acting injectable antipsychotics on caregivers' burden of patients with schizophrenia. 长效注射抗精神病药物的疗效对精神分裂症患者护理负担的影响。

IF 3 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-02-22 DOI: 10.1097/YIC.0000000000000539

Enrico Capuzzi, Cecilia Quitadamo, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli

引用次数: 0

The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia. 早或晚服用长效抗精神病药物对精神分裂症患者照顾者负担的影响。

IF 3 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-11-23 DOI: 10.1097/YIC.0000000000000524

Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü

{"title":"The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia.","authors":"Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü","doi":"10.1097/YIC.0000000000000524","DOIUrl":"10.1097/YIC.0000000000000524","url":null,"abstract":"The effective treatment in the early stages of schizophrenia is of critical importance to improve the prognosis. Schizophrenia affects patients' relatives too. The effects of early or late initiation of long-acting injectable antipsychotics (LAI-APs) on the patient have been shown, yet their effects on the caregiver are still unknown. We aimed to determine how the time of initiation of LAI-APs affects the caregiver burden by comparing the patients who were started on LAI-APs in the first 5 years of diagnosis and those who were started at a later period. Patients were classified as 'early-LAI' and 'late-LAI' according to the time of initiation of a LAI-AP. Their caregivers were also classified as the same way, as 'caregiver-early' and 'caregiver-late' and were compared in terms of caregiver burden. The quality of life, depression, anxiety, and caregiver burden scores of the caregiver-late group were significantly worse. The time of initiation of LAI-APs and the functioning levels of the patients were found to be determinant factors for the caregiver burden. This is the first study to investigate the effects of LAI-AP's initiation time on the caregivers to our knowledge. The use of LAI-APs in the early stages is associated with better outcomes for the caregiver.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"313-322"},"PeriodicalIF":3.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0